CANADABIS CAPITAL INC (CANB.CA) Stock Fundamental Analysis
Canada - TSX Venture Exchange - TSX-V:CANB - CA13530Q1046 - Common Stock
0.02 CAD
-0.01 (-20%)
Taking everything into account, CANB scores 2 out of 10 in our fundamental rating. CANB was compared to 32 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of CANB while its profitability can be described as average. CANB has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year CANB has reported negative net income.
In the past year CANB has reported a negative cash flow from operations.
In multiple years CANB reported negative net income over the last 5 years.
In the past 5 years CANB reported 4 times negative operating cash flow.
1.2 Ratios
CANB's Return On Assets of -3.40% is fine compared to the rest of the industry. CANB outperforms 62.50% of its industry peers.
With a decent Return On Equity value of -10.67%, CANB is doing good in the industry, outperforming 62.50% of the companies in the same industry.
CANB has a Return On Invested Capital of 4.06%. This is in the better half of the industry: CANB outperforms 68.75% of its industry peers.
CANB had an Average Return On Invested Capital over the past 3 years of 12.44%. This is above the industry average of 8.14%.
The last Return On Invested Capital (4.06%) for CANB is well below the 3 year average (12.44%), which needs to be investigated, but indicates that CANB had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.4% | ||
| ROE | -10.67% | ||
| ROIC | 4.06% |
ROA(3y)6.13%
ROA(5y)0.44%
ROE(3y)19.38%
ROE(5y)-14.57%
ROIC(3y)12.44%
ROIC(5y)N/A
1.3 Margins
CANB's Operating Margin of 3.53% is fine compared to the rest of the industry. CANB outperforms 71.88% of its industry peers.
In the last couple of years the Operating Margin of CANB has declined.
Looking at the Gross Margin, with a value of 44.53%, CANB is in the better half of the industry, outperforming 65.63% of the companies in the same industry.
CANB's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.53% | ||
| PM (TTM) | N/A | ||
| GM | 44.53% |
OM growth 3Y-28.69%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.68%
GM growth 5Y5.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CANB is creating value.
Compared to 1 year ago, CANB has about the same amount of shares outstanding.
Compared to 5 years ago, CANB has more shares outstanding
The debt/assets ratio for CANB is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.15, we must say that CANB is in the distress zone and has some risk of bankruptcy.
CANB has a Altman-Z score (0.15) which is in line with its industry peers.
CANB has a Debt/Equity ratio of 0.64. This is a neutral value indicating CANB is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.64, CANB is doing worse than 68.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.64 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.15 |
ROIC/WACC0.72
WACC5.67%
2.3 Liquidity
A Current Ratio of 1.06 indicates that CANB should not have too much problems paying its short term obligations.
With a Current ratio value of 1.06, CANB is not doing good in the industry: 81.25% of the companies in the same industry are doing better.
A Quick Ratio of 0.24 indicates that CANB may have some problems paying its short term obligations.
CANB has a worse Quick ratio (0.24) than 90.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.24 |
3. Growth
3.1 Past
The earnings per share for CANB have decreased strongly by -241.86% in the last year.
The Revenue has decreased by -5.87% in the past year.
The Revenue has been growing by 30.72% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-241.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-270.83%
Revenue 1Y (TTM)-5.87%
Revenue growth 3Y13.14%
Revenue growth 5Y30.72%
Sales Q2Q%-6.63%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CANB. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CANB is valued cheaper than 87.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 6.08 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
CANB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX-V:CANB (12/22/2025, 7:00:00 PM)
0.02
-0.01 (-20%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners53.52%
Ins Owner ChangeN/A
Market Cap2.76M
Revenue(TTM)16.90M
Net Income(TTM)-835.20K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.16 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.35 | ||
| P/tB | 0.35 | ||
| EV/EBITDA | 6.08 |
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.12
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.4% | ||
| ROE | -10.67% | ||
| ROCE | 5.58% | ||
| ROIC | 4.06% | ||
| ROICexc | 4.34% | ||
| ROICexgc | 4.34% | ||
| OM | 3.53% | ||
| PM (TTM) | N/A | ||
| GM | 44.53% | ||
| FCFM | N/A |
ROA(3y)6.13%
ROA(5y)0.44%
ROE(3y)19.38%
ROE(5y)-14.57%
ROIC(3y)12.44%
ROIC(5y)N/A
ROICexc(3y)15.4%
ROICexc(5y)N/A
ROICexgc(3y)15.4%
ROICexgc(5y)N/A
ROCE(3y)15.95%
ROCE(5y)N/A
ROICexgc growth 3Y-38.64%
ROICexgc growth 5YN/A
ROICexc growth 3Y-38.64%
ROICexc growth 5YN/A
OM growth 3Y-28.69%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.68%
GM growth 5Y5.67%
F-Score1
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.64 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 3.39 | ||
| Cap/Depr | 19.2% | ||
| Cap/Sales | 1% | ||
| Interest Coverage | 2.21 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.24 | ||
| Altman-Z | 0.15 |
F-Score1
WACC5.67%
ROIC/WACC0.72
Cap/Depr(3y)67.82%
Cap/Depr(5y)55.13%
Cap/Sales(3y)2.43%
Cap/Sales(5y)2.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-241.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-270.83%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-5.87%
Revenue growth 3Y13.14%
Revenue growth 5Y30.72%
Sales Q2Q%-6.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-27.8%
EBIT growth 3Y-19.31%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-466.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1146.98%
OCF growth 3YN/A
OCF growth 5YN/A
CANADABIS CAPITAL INC / CANB.CA FAQ
Can you provide the ChartMill fundamental rating for CANADABIS CAPITAL INC?
ChartMill assigns a fundamental rating of 2 / 10 to CANB.CA.
What is the valuation status for CANB stock?
ChartMill assigns a valuation rating of 1 / 10 to CANADABIS CAPITAL INC (CANB.CA). This can be considered as Overvalued.
How profitable is CANADABIS CAPITAL INC (CANB.CA) stock?
CANADABIS CAPITAL INC (CANB.CA) has a profitability rating of 4 / 10.